Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KIMUN is a dietary supplement developed and marketed by biosyn Arzneimittel GmbH, primarily designed to support the immune system. It contains a combination of sodium selenite pentahydrate, which serves as a source of selenium, along with a blend of amino acids including L-glutamic acid, L-aspartic acid, L-leucine, and L-lysine. Additionally, the formulation includes small quantities of spleen and thymus extracts. KIMUN is produced as capsules containing micro-pellets that are engineered to protect the active ingredients from the acidic environment of the stomach, ensuring they are released in the small intestine. It is marketed in Germany for individuals with weakened immune systems or those under significant physical or mental stress.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on KIMUN.